Our Pipeline

Mycovia is committed to the development of a robust pipeline of novel therapies to address the needs of patients living with overlooked medical conditions in women’s health and beyond.

Product Candidates
Phase 1
Phase 2
Phase 3
NDA Submitted
Oteseconazole (VT-1161)
Invasive & opportunistic infections
Emerging MDR-fungi (Candida auris)
Cryptococcal meningitis (Cryptococcus neoformans)
Valley fever (Coccidioides)

Source: Mycovia Source Data on File
*VT-1598 has QIDP designation, Fast Track status, and orphan designation for Valley fever (coccidioides); cryptococcal meningitis is eligible for FDA’s priority review voucher program.

Worldwide clinical trials were completed for oteseconazole.

Find out more

Page Banner Image

Our passion for medicine doesn’t end at women’s health.

Mycovia is currently evaluating VT-1598, an oral antifungal, in Phase 1 clinical trials, for the treatment of serious fungal pathogens that pose a growing global threat due to underlying multidrug resistance.